Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Bb-2516
1. 154039-60-8
2. Bb-2516
3. Bb 2516
4. Bb2516
5. D5eqv23tds
6. Nsc-719333
7. Gi5712
8. Kb-r 8898
9. Ta2516
10. Gi-5712
11. Ta-2516
12. (2s,3r)-3-(((1s)-2,2-dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid
13. Chebi:50662
14. Dtxsid20165524
15. Nsc689451
16. Nsc719333
17. Marimistat
18. (2s,3r)-n-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n',2-dihydroxy-3-(2-methylpropyl)butanediamide
19. Marimastatum
20. (2s,3r)-n-((1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl)-n',2-dihydroxy-3-(2-methylpropyl)butanediamide
21. Refchem:810621
22. Dtxcid3088015
23. (2s,3r)-3-((s)-(2,2-dimethyl-1-(methylcarbamoyl) Propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic Acid
24. Marimastat (bb-2516)
25. (2r,3s)-n1-((s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-n4,3-dihydroxy-2-isobutylsuccinamide
26. (2r,3s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-n',3-dihydroxy-2-(2-methylpropyl)butanediamide
27. Mfcd00866242
28. Bb2516;ta2516
29. Chembl279785
30. Marimastat [usan]
31. (2s,3r)-3-(((1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic Acid
32. (2s,3r)-n(4)-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-n(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
33. (2r)-n-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxo-ethyl]-4-methyl-pentanamide
34. (2s,3r)-n~4~-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n~1~,2-dihydroxy-3-(2-methylpropyl)butanediamide
35. Butanediamide, N4-((1s)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s,3r)-
36. Butanediamide, N4-[(1s)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s,3r)-
37. Smr002530328
38. Marimastat (usan/inn)
39. Unii-d5eqv23tds
40. Marimastat [usan:inn:ban]
41. (2s,3r)-3-[[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]carbamoyl]-2-hydroxy-5-methylhexanohydroxamic Acid
42. Butaneamide,2-dimethyl-1-[(methylamino)carbonyl]propyl]- N1,2-dihydroxy-3-(2-methylpropyl)-, (2s,3r)-
43. 3hy7
44. Marimastat [mi]
45. Marimastat [inn]
46. D03795
47. Marimastat [mart.]
48. Marimastat [who-dd]
49. Schembl34033
50. Mls003899230
51. Mls006010669
52. Cid_119031
53. Gtpl5220
54. Orb1300377
55. Marimastat, >=98% (hplc)
56. Ex-a643
57. Glxc-06760
58. Bdbm50063917
59. S7156
60. Akos024457206
61. Ccg-267821
62. Cs-3456
63. Db00786
64. Gi 5712
65. Nsc 719333
66. Nsc-689451
67. Ta 2516
68. Marimastat - Cas 154039-60-8
69. (2s,3r)-n'-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n,2-dihydroxy-3-(2-methylpropyl)butanediamide
70. Ac-35828
71. As-57129
72. Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2s-(n(sup 4)(r*),2r*,3s*))-
73. Butanediamide, N4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s-(n4(r*),2r*,3s*))-
74. Fm161188
75. Hy-12169
76. Ns00068619
77. Q6763659
78. Brd-k21396683-001-04-8
79. (2s,3r)-n4-[(1s)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-n1,2-dihydroxy-3-(2-methylpropyl)butanediamide;bb 2516;ta 2516
80. Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s-(n4(r*),2r*,3s*))-
| Molecular Weight | 331.41 g/mol |
|---|---|
| Molecular Formula | C15H29N3O5 |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 128 |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 431 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of various cancers
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Marimastat is a broad spectrum matrix metalloprotease inhibitor. It mimics the peptide structure of natural MMP substrates and binds to matrix metalloproteases, thereby preventing the degradation of the basement membrane by these proteases. This antiprotease action prevents the migration of endothelial cells needed to form new blood vessels. Inhibition of MMPs also prevents the entry and exit of tumor cells into existing blood cells, thereby preventing metastasis.
ABOUT THIS PAGE
78
PharmaCompass offers a list of Marimastat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Marimastat manufacturer or Marimastat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Marimastat manufacturer or Marimastat supplier.
A Marimastat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Marimastat, including repackagers and relabelers. The FDA regulates Marimastat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Marimastat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Marimastat supplier is an individual or a company that provides Marimastat active pharmaceutical ingredient (API) or Marimastat finished formulations upon request. The Marimastat suppliers may include Marimastat API manufacturers, exporters, distributors and traders.
Marimastat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Marimastat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Marimastat GMP manufacturer or Marimastat GMP API supplier for your needs.
A Marimastat CoA (Certificate of Analysis) is a formal document that attests to Marimastat's compliance with Marimastat specifications and serves as a tool for batch-level quality control.
Marimastat CoA mostly includes findings from lab analyses of a specific batch. For each Marimastat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Marimastat may be tested according to a variety of international standards, such as European Pharmacopoeia (Marimastat EP), Marimastat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Marimastat USP).
